Renal cancer biomarkers: the promise of personalized care

摘要: Significant advances in our understanding of the biology renal cell carcinoma (RCC) have been achieved recent years. These insights led to introduction novel targeted therapies, revolutionising management patients with advanced disease. Nevertheless, there are still no biomarkers routine clinical use RCC. Tools used routinely determine prognosis not changed over past decade; classification remains largely morphology based; and continue be exposed potentially toxic therapy indication likelihood response. Thus need for RCC is urgent. Here, we focus on genetics epigenetics RCC, potential such knowledge provide markers therapeutic targets. We highlight on-going research that likely deliver further candidate as well generating large, well-annotated sample banks will facilitate future studies. It imperative promising candidates validated using these resources, subsequent prospective trials, so may clinic personalize patient care.